Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1974 1
1979 1
1980 2
1986 1
1989 2
1990 1
1993 2
1994 1
1995 1
1997 1
1998 1
2002 2
2003 3
2005 1
2006 3
2007 4
2008 4
2010 2
2011 6
2012 5
2013 7
2014 7
2015 5
2016 7
2017 7
2018 13
2019 9
2020 4
2021 10
2022 5
2023 9
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders.
Ambrus-Aikelin G, Takeda K, Joetham A, Lazic M, Povero D, Santini AM, Pranadinata R, Johnson CD, McGeough MD, Beasley FC, Stansfield R, McBride C, Trzoss L, Hoffman HM, Feldstein AE, Stafford JA, Veal JM, Bain G, Gelfand EW. Ambrus-Aikelin G, et al. Among authors: stansfield r. Sci Rep. 2023 Aug 19;13(1):13524. doi: 10.1038/s41598-023-39805-z. Sci Rep. 2023. PMID: 37598239 Free PMC article.
Health Disparities Educational Initiative for Residents.
Benson BL, Ha M, Stansfield RB, Markova T. Benson BL, et al. Among authors: stansfield rb. Ochsner J. 2018 Summer;18(2):151-158. doi: 10.31486/toj.17.0082. Ochsner J. 2018. PMID: 30258297 Free PMC article.
Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Povero D, Lazic M, McBride C, Ambrus-Aikelin G, Stansfield R, Johnson CD, Santini AM, Pranadinata RF, McGeough MD, Stafford JA, Hoffman HM, Feldstein AE, Veal JM, Bain G. Povero D, et al. Among authors: stansfield r. J Pharmacol Exp Ther. 2023 Aug;386(2):242-258. doi: 10.1124/jpet.123.001639. Epub 2023 Jun 12. J Pharmacol Exp Ther. 2023. PMID: 37308266
Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor.
McBride C, Trzoss L, Povero D, Lazic M, Ambrus-Aikelin G, Santini A, Pranadinata R, Bain G, Stansfield R, Stafford JA, Veal J, Takahashi R, Ly J, Chen S, Liu L, Nespi M, Blake R, Katewa A, Kleinheinz T, Sujatha-Bhaskar S, Ramamoorthi N, Sims J, McKenzie B, Chen M, Ultsch M, Johnson M, Murray J, Ciferri C, Staben ST, Townsend MJ, Stivala CE. McBride C, et al. Among authors: stansfield r. J Med Chem. 2022 Nov 10;65(21):14721-14739. doi: 10.1021/acs.jmedchem.2c01250. Epub 2022 Oct 24. J Med Chem. 2022. PMID: 36279149
106 results